Table 2 Multivariate logistic regression of the risk of requiring CKD-related pharmacotherapy during the pre-dialysis period

Risk for requiring ESAs during the pre-dialysis period

 VDRA at referral

0.052

1.61 (0.99–2.60)

 Iron at referral

0.042

1.85 (1.02–3.35)

 eGFR at referral

0.026

0.95 (0.92–0.99)

 Hemoglobin ref. < 100 g/l

0.053

2.24 (0.99–4.60)

 Hemoglobin ref. 100- 120 g/l

0.040

2.18(1.28–3.71)

 iPTH ref. > 150 ng/l

0.044

1.66(1.01–2.73)

Risk for requiring iron therapy during the pre-dialysis period

 eGFR ref. (CKD-EPI)

 < 0.001

0.93 (0.89–0.97)

 ESAs at referral

0.058

2.02 (0.98–4.17)

Risk for requiring phosphate binders during the pre-dialysis period

 Age > 80

0.03

0.20 (0.07–0.58)

 Age 50–60

0.09

0.47 (0.18–1.15)

 Age 61–70

0.08

0.33 (0.15–0.75)

 Age 71–80

0.02

0.28 (0.13–0.64)

 iPTH ref. > 150 ng/l

0.03

2.33 (1.33–4.04)

 Hemoglobin ref. < 100 g/l

0.009

2.75 (1.29–5.86)

 Hemoglobin ref. 100- 120 g/l

0.70

1.13 (0.6–2.09)

 Serum albumin > 35 g/l

0.10

2.46 (1.29–5.86)

 eGFR ref. (CKD-EPI)

0.05

0.93 (0.90–0.98)

Risk for requiring VDRA during the pre-dialysis period

 History of diabetes

0.025

1.55 (1.06–4.77)

 Serum albumin > 35 g/l

0.016

2.40 (1.18–4.91)

 Calcium < 2.1 mmol/l

0.189

1.54 (0.81–2.93)

 Calcium > 2.6 mmol/l

0.040

2.27 (1.04–4.96)

 iPTH > 150 ng/l

 < 0.001

3.2 (2.15–4.77)